Abeona Therapeutics (NASDAQ:ABEO) Price Target Raised to $20.00

Abeona Therapeutics (NASDAQ:ABEO) had its target price increased by HC Wainwright from $15.00 to $20.00 in a research note released on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.57 EPS.

ABEO has been the topic of a number of other reports. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.75.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $6.56 on Wednesday. The business’s 50 day moving average is $5.09 and its 200-day moving average is $5.62. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $320.13 million, a PE ratio of -2.44 and a beta of 1.71. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.19. Sell-side analysts predict that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now owns 1,355,322 shares of the company’s stock, valued at $6,478,439.16. This represents a 1.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abeona Therapeutics

A number of large investors have recently modified their holdings of the stock. Cannon Global Investment Management LLC bought a new position in Abeona Therapeutics in the 1st quarter worth approximately $67,000. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics during the fourth quarter valued at $520,000. Western Standard LLC boosted its holdings in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after acquiring an additional 386,321 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics during the 4th quarter worth about $67,000. Finally, Twinbeech Capital LP acquired a new position in Abeona Therapeutics during the 4th quarter valued at about $58,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.